Importantly, survival analysis revealed that GC patients with low expression of SPI1 had a better prognosis compared with GC patients with high expression of SPI1 (see Figs. S1, http://links.lww.com/MD/I518 and S2, http://links.lww.com/MD/I519, Supplemental Content, which illustrates the expression of SPI1), which was consistent with the observation that GC patients with low AKR6A5 expression have a better prognosis than GC patients with high AKR6A5 expression (Fig. 4). The gene discussed is KCNAB2; the disease is gastric cancer.